Julia Kodysh

Icahn School of Medicine at Mount Sinai — United States

Immunology and Microbiology · Life Sciences

12h-index2.7kcitations51works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(37), vaccines and immunoinformatics approaches(33), Monoclonal and Polyclonal Antibodies Research(19), SARS-CoV-2 and COVID-19 Research(7), Cancer Genomics and Diagnostics(7)

Publications51 total

T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome
iScience·2025· 1 citedOpen Access
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial
Nature Cancer·2025· 7 cited
Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025· 1 citedOpen Access
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Cancer Discovery·2025· 12 cited
CTIM-10. PHASE 1 TRIAL OF PERSONALIZED NEOANTIGEN VACCINES IN COMBINATION WITH STANDARD CARE TO TREAT GLIOBLASTOMA
Neuro-Oncology·2024· 1 citedOpen Access
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.
2024· 2 citedOpen Access
Abstract LB113: Immunogenicity of Atezolizumab plus personalized neoantigen vaccination (PGV-001) in patients with urothelial cancer in adjuvant vs metastatic setting
Cancer Research·2024
Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer.
Journal of Clinical Oncology·2024· 5 cited
page 1 of 3Next →

Frequent Co-authors

Alex Rubinsteyn(43), Nina Bhardwaj(38), Timothy J. O’Donnell(25), Marcia Meseck(24), John P. Finnigan(23), Mansi Saxena(22), Jeff Hammerbacher(21), Rachel Brody(20), Thomas U. Marron(19), Cansu Cimen Bozkus(18), Samir Parekh(18), Hanna Y. Irie(18), Sacha Gnjatic(18), Philip Friedlander(18), Brett A. Miles(17), Amy Tiersten(17), Andrea Wolf(17), John Mandeli(17), Eric E. Schadt(17), Robert Sebra(16)